Intercept Pharmaceuticals, Inc.

ICPT

$37.39

-56.98% (1 year change)

Avg closing price

Price range

Market Cap

$1.18 Billion

The market capitalization is the market value of the company. It is the sum of the value of all outstanding shares.

Revenue

-

Total revenue in the last quarter.

Net Income

-

Net income is all revenues minus all expenses including taxes and interest in the last quarter.

Earnings per Share

$-9.78

Earnings per share is the amount of net income that is attributed to each single share outstanding.

Dividends per Share

-

Dividends per share is the amount of dividends paid out to the shareholder of a single share in the last 12 months. The percentage indicates the ratio of the company's annual dividend compared to its current price per share (stock price).

Price-Earnings Ratio

-3.64x

The price-earnings ratio is the ratio between the price per share (stock price) and the earnings per share. It indicates the percentage of the price per share (stock price) that is generated in earnings in the last 12 months.

EBIT

-

Earnings before interest expenses and taxes in the last quarter.

Employees

583

The number of full time employees.

Revenue & Earnings

Balance Sheet

Intercept Pharmaceuticals, Inc.

Intercept Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics in treating chronic liver diseases. Its product pipeline is OCALIVA which is used for the treatment of primary biliary cholangitis, nonalcoholic steatohepatitis, primary sclerosing cholangitis, and biliary atresia. The company was founded by Mark E. Pruzanski and Roberto Pellicciari on September 4, 2002 and is headquartered in New York, NY.

News

ROSEN, A LEADING LAW FIRM, Reminds Intercept Pharmaceuticals, Inc. Investors of Important January 4 Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact Firm - ICPT

ROSEN, A LEADING LAW FIRM, Reminds Intercept Pharmaceuticals, Inc. Investors of Important January 4 Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact Firm - ICPT

NEW YORK, Nov. 24, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) between September 2...

PR Newswire PR Newswire, 2 days ago
ROSEN, GLOBALLY RECOGNIZED INVESTOR COUNSEL, Reminds Intercept Pharmaceuticals, Inc. Investors of Important Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact Firm – ICPT

ROSEN, GLOBALLY RECOGNIZED INVESTOR COUNSEL, Reminds Intercept Pharmaceuticals, Inc. Investors of Important Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact Firm – ICPT

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) between September 28, 2019 and O...

Business Wire Business Wire, 6 days ago
New Data from the Interim Analysis of REGENERATE Show OCA Improved Noninvasive Measures of Fibrosis in a Subgroup of High-Risk Patients with Fibrosis Due to NASH

New Data from the Interim Analysis of REGENERATE Show OCA Improved Noninvasive Measures of Fibrosis in a Subgroup of High-Risk Patients with Fibrosis Due to NASH

Multiple new analyses reinforce the clinical value of noninvasive strategies to identify and monitor patients with advanced fibrosis due to NASHNEW YORK, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Intercept...

Yahoo Finance Yahoo Finance, 11 days ago